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Abstract
Background: Liver biopsy represents the gold standard for evaluating damage and progression in patients with chronic
hepatitis C (CHC); however, developing noninvasive tests that can predict liver injury represents a growing medical need.
Considering that hepatocyte apoptosis plays a role in CHC pathogenesis; the aim of our study was to evaluate the presence
of different apoptosis markers that correlate with liver injury in a cohort of pediatric and adult patients with CHC.
Methods: Liver biopsies and concomitant serum samples from 22 pediatric and 22 adult patients with CHC were analyzed.
Histological parameters were evaluated. In serum samples soluble Fas (sFas), caspase activity and caspase-generated
neoepitope of the CK-18 proteolytic fragment (M30) were measured.
Results: sFas was associated with fibrosis severity in pediatric (significant fibrosis p = 0.03, advanced fibrosis p = 0.01) and
adult patients (advanced fibrosis p = 0.02). M30 levels were elevated in pediatric patients with severe steatosis (p = 0.01)
while in adults no relation with any histological variable was observed. Caspase activity levels were higher in pediatric
samples with significant fibrosis (p = 0.03) and they were associated with hepatitis severity (p = 0.04) in adult patients. The
diagnostic accuracy evaluation demonstrated only a good performance for sFas to evaluate advanced fibrosis both in
children (AUROC: 0.812) and adults (AUROC: 0.800) as well as for M30 to determine steatosis severity in children (AUROC:
0.833).
Conclusions: Serum sFas could be considered a possible marker of advanced fibrosis both in pediatric and adult patient
with CHC as well as M30 might be a good predictor of steatosis severity in children.
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Introduction
Hepatitis related to Hepatitis C virus (HCV) is a progressive
disease that may result in chronic active hepatitis, cirrhosis, and
hepatocellular carcinoma. It is estimated that over 200 million
people are infected worldwide, while 80% develop a chronic form
[1]. It represents a global health problem since there is no vaccine
available, the response to current standard of care therapy is
limited and liver failure related to chronic hepatitis C (CHC) virus
infection is one of the most common reasons for liver transplants
[2]. Liver disease seems to be milder in children than in adults;
however, the natural history of HCV infection acquired in infancy
and childhood remains poorly characterized and the long-term
outcome of the disease is still a matter of debate [3].
Although liver biopsy represents the gold standard for
evaluating presence, type and stage of liver fibrosis and for
characterizing necroinflammation; it remains an expensive and
invasive procedure with inherent risks. Thus, it cannot be
performed frequently to monitor therapeutic outcomes [4,5].
Moreover, in children, biopsy is still perceived to carry a higher
risk of complications, so it is less accepted than in adults.
Therefore, developing noninvasive tests that can accurately predict
initial disease stage and progression over time represents a high
priority and growing medical need [6,7].
Several less invasive diagnostic methods are currently being
validated as potential tools to determine liver damage, namely
serum markers and image methods, but they have not been yet
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incorporated in clinical practice in most countries [8]. Many
authors have proposed multiple indexes based on the combination
of biochemical markers with clinical data (i.e. Fib-4, Forms or
Fibrotest) or biochemical and clinical markers with fibrosis
parameters (i.e. Hepascore, Shasta and Fibrometer) to predict
fibrosis stage [9,10,11,12,13,14]. Related to that, we have
previously studied, in a cohort of pediatric and adult patients,
the presence of a pro-fibrogenic cytokine (TGF-ß1) as well as
different matrix deposition markers [hyaluronic acid (HA), type III
procollagen amino-terminal peptide (PIIINP) and tissue inhibitor
of matrix metalloprotein inhibitor-1 (TIMP-1)] related to liver
injury during CHC. The results demonstrated that given the
diagnostic accuracy of HA, PIIINP, TGF-ß1, their combination
may provide a potential useful tool to assess liver fibrosis in adults.
On the other hand, in pediatric patients TIMP-1 could be
clinically useful for predicting liver fibrosis in patients with CHC
[15].
Considering that 1) apoptosis plays a major role in the tissue
development and homeostasis and in pathological processes [16];
2) it has been demonstrated that hepatocyte apoptosis plays a role
in liver pathogenesis of CHC; as well as it may be associated with
liver fibrogenesis [17,18,19,20]; the aim of our study was to
evaluate the presence of different apoptosis markers which
correlate with liver injury in a cohort of pediatric and adult
patients with CHC infection.
Methods
Patients and samples
Twenty two pediatric patients with CHC (8 male, 14 female;
range of age at biopsy: 1–17 years, median: 8 years) from Hospital
de Nin˜os Ricardo Gutierrez (HNRG) and 22 adult patients (13
male, 9 female; range of age at biopsy: 38–74 years, median: 51
years) from Hospital Italiano de Buenos Aires (HIBA) were
enrolled in the present study.
Diagnosis was based on the presence of anti-HCV antibodies in
serum at or after 18 months of age and HCV RNA in plasma at
one or more separate occasions. Patients had no other causes of
liver disease, autoimmune or metabolic disorders, hepatocellular
carcinoma and coinfection with hepatitis B virus and/or human
immunodeficiency virus. In adult cases, patients with a history of
habitual alcohol consumption were excluded (.80 g/day for men
and .60 g/day for women). Patients were naı¨ve of treatment.
This study has the approval of the Institutional Review Board and
the Ethics Board of both HNRG and HIBA and is also in
accordance with the Helsinki Declaration of 1975, as revised in
1983. A written informed consent was obtained from all the
included adult patients and from parents of pediatric patients after
the nature of the procedure had been fully explained.
Formalin-fixed paraffin-embedded liver biopsies and serum
samples at time of biopsy were used for histological and serological
analysis, respectively. Histological sections were evaluated by two
independent pathologists in a blind manner. Inflammatory activity
and fibrosis were assessed using the modified Knodell scoring
system (Histological Activity Index, HAI) and METAVIR [21].
According to HAI, each biopsy specimen was categorized as
minimal (#3), mild (4–6), moderate (7–12) or severe hepatitis
(.12). Presence of lymphoid follicles as well as of bile duct lesion
and grade of steatosis were also evaluated. Steatosis was graded as
follows: minimal (1–33% of hepatocytes affected), moderate,
(.33%–66%) or severe (.66%). Serum AST and ALT levels
and genotype were obtained from clinical records. As controls,
serum samples from pediatric (n = 9) and adult (n = 9) healthy
subjects without known systemic or liver disease and with normal
biological liver test as well as absence of anti-HCV antibodies,
were included.
In adult cases, liver samples were not obtained from patients
diagnosed as having liver cirrhosis based on clinical, biochemical
and imaging findings. Although, there are no pediatric specific
guidelines about the need for and timing of a liver biopsy in
children, the probability of a child undergoing liver biopsy in this
study reflected the current practice at our centre, which is based
mostly on the national experts consensus [22]. In two pediatric
cases, more than one sample was available.
Quantitative assessment of apoptosis markers
Soluble Fas (sFas), caspase activity and caspase-generated
neoepitope of the CK-18 proteolytic fragment (M30) were
measured as apoptosis markers.
Serum sFas and M30 were determined by commercial
quantitative sandwich enzyme immunoassay technique (Quantikine
Human soluble Fas kit, R&D Systems Inc; and M30-Apoptosense
ELISA kit, PEVIVA; respectively) according to the manufacturer’s
instructions. Serum concentration for each marker was deter-
mined from standard curves. Serum sFas was expressed as pg/mL
and M30 as U/L.
Serum Caspase activity was determined using a chemilumines-
cence assay (Caspase-Glo Assay, Promega). Briefly, samples were
first diluted 1:1 in a buffer containing 50 mM Tris-HCl, 10 mM
KCl, 5% glycerol, pH 7.4 and incubated with 25 ml of samples or
controls diluted with an equal volume of caspase substrate for 3 h
at room temperature. Then, the samples’ luminescence was
measured for 20 seconds in the Luminometer Junior LB 9509
(Berthold Technologies GmbH & Co. KG). Results are expressed as
RLU. An activity negative control (25 ml buffer 50 mM Tris-HCl,
10 mM KCl, 5% glycerol, pH 7.4) and positive control (25 ml
Human Recombinant activated Caspase-3 Protein, Millipore,
CHEMICON 0.04 U/ml in the same buffer) were included in
each assay.
Each serum marker concentration was assessed in duplicate.
Operators who perform the laboratory tests were blinded for
patient’s clinical and histological data.
Statistical analysis
Statistical analysis was performed using GraphPad InStat
software, version 3.05. To compare the means between groups,
ANOVA or Student’s t test were performed. To determine
differences between groups not normally distributed, medians
were compared using the Mann-Whitney U test or Kruskal Wallis
test. Pearson’s correlation coefficient was used to measure the
degree of association between continuous, normally distributed
variables. The degree of association between non-normally
distributed variables was assessed using Spearman’s nonparamet-
ric correlation. To compare categorical variables Fisher’s exact
Test was applied. P values,0.05 were considered statistically
significant. The results are depicted in box plots. Horizontal lines
within boxes indicate medians. Horizontal lines outside the boxes
represent the 5 and 95 percentiles. Mean is indicated as +.
To assess the ability of the serum apoptosis markers to
differentiate hepatitis grade, fibrosis stages and steatosis grade,
we calculated the sensitivity and the specificity for each value of
each marker and then constructed receiver operating character-
istic (ROC) curves by plotting the sensitivity against the reverse
specificity at each value. The diagnostic value of each serum
marker was assessed by the area under the ROC (AUROC).
AUROC of 1.0 is characteristic of an ideal test, whereas 0.5
indicates a test of no diagnostic value. We determined the cut-off
value for the diagnosis, as the maximal value at the sum of the
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sensitivity (Se) and specificity (Sp). The diagnostic accuracy was
calculated by sensitivity, specificity and positive and negative
predictive values. Area under the ROC, cut off values, positive
predictive values (PPV) and negative predictive values (NPV) were
determined using the MedCalc demo statistical software (Mar-
iakerke, Belgium).
Results
Clinical and liver biopsy findings
Clinical, virological, and histological features of patients are
described in Table 1 (pediatric patients) and Table 2 (adult
patients).
In both groups HCV genotype 1 was predominant, 86% in
pediatric cases and 77% in adults. The risk factors for HCV
infection in children were 46% vertical transmission, 36%
transfusion and 18% unknown. In adults, seven cases (32%) had
a history of injecting drug abuse, one case (5%) described an
occupational exposure to infected blood, four (18%) a transfusion
as a risk factor and 10 (45%) an unknown source for transmission.
The aspartate aminotransferase (AST) and alanine aminotrans-
ferase (ALT) levels at time of biopsy, considering multiple biopsies
from the same patient in 2 pediatric cases, were elevated in 52%
and 76% serum samples of pediatric patients, respectively and in
59% and 77% serum samples of adult patients as well.
Eighteen percent of pediatric biopsies showed moderate or
severe hepatitis, while concerning fibrosis, bridging fibrosis (stage 2
of METAVIR) was predominant among studied biopsies (44%). In
adult cases, moderate or severe hepatitis were present in 73% of
biopsies and the fibrosis profile displayed was 32% stage 1, 32%
stage 2 and 23% stage 3. Finally, 3 adult patients showed absence
of fibrosis. The prevalence of significant fibrosis (F$2) and
advanced fibrosis (F$3) in the pediatric cohort were 64% and
20%, respectively; meanwhile it was 54% F$2 and 23% F$3 in
adults. Lymphoid follicles, characteristic of CHC in adults, were
present in 40% of pediatric and 82% of adult specimens, whereas
bile duct lesions were observed in 83% of pediatric and 95% of
adult samples. Hepatocellular fat accumulation, typically a
mixture of small and large droplet fat, was present in both series
(64% of pediatric and 50% of adult cases). Minimal steatosis was
observed in 36%, moderate in 12% and severe in 16% of pediatric
biopsies; meanwhile in adults minimal, moderate and severe
steatosis were present in 27%, 9% and 14%, respectively. The
comparative statistical analysis of all histological parameters
between pediatric and adult studied patients did not showed any
significant difference except for lymphoid follicles (p = 0.01).
However, it should be taken into account that adult cases with
liver cirrhosis based on clinical, biochemical and imaging findings
were not biopsied.
Finally, aminotransferase values were not associated to any
parameter of histological liver damage.
Quantitative assessment of sFas, caspase activity and
M30
Apoptosis markers were first compared between patients with
CHC and healthy subjects. Then in a further analysis CHC
patients apoptosis markers were related to histological parameters
of liver injury, particularly fibrosis, hepatitis and steatosis severity.
As it is shown in Figure 1, apoptosis markers were significantly
increased in serum samples from both pediatric and adult patients
with CHC compared to healthy subjects, except for sFas levels in
CHC pediatric patient samples which only showed a trend of
association (p = 0.07).
With regard to liver damage, sFas was associated with fibrosis
severity in both pediatric and adult CHC patients. It was
significantly increased in children with significant fibrosis
(p = 0.03) and advanced fibrosis (p = 0.01), and in adults with
advanced fibrosis (p = 0.02) (Figure 2a). It is worth mentioning that
serum sFas levels of pediatric patients with mild fibrosis stages (F1
and F2) showed no significant differences compared with those
levels of pediatric healthy subjects. It is in accordance with most
noninvasive makers that offer most reliable results at the extreme
fibrosis stages. Finally, sFas was not associated with hepatitis
severity or steatosis degree in any of the studied age groups
(Figure 2b, c).
The M30 association profile related to the histological
parameters was different between children and adults. In pediatric
cases, M30 levels were elevated in patients with severe steatosis
(p = 0.01) (Figure 2c) while in adults no relation with this
histological variable was observed. Concerning fibrosis a trend of
association between this marker and advanced fibrosis (p = 0.05) in
adults was depicted (Figure 2a). Finally, there were no significant
differences in serum M30 levels with respect to hepatitis in none of
the studied age groups (Figure 2b).
The caspase activity profile in relation to fibrosis severity was
similar to that observed for sFas and M30 in both populations.
Caspase activity levels were higher in those cases with significant
and advanced fibrosis; however, the difference turned out to be
statistically significant only in samples from children with
significant fibrosis (p = 0.03). In the adult cohort only a trend of
association with significant fibrosis was observed (p = 0.08). In
turn, in serum samples from adult patients caspase activity was
associated with hepatitis severity (p = 0.04) (Figure 2b). No
association between steatosis degree and caspase activity was
observed in any of the studied groups (Figure 2c).
Diagnostic performance of apoptosis markers
The evaluation of the diagnostic performance was only assessed
for those apoptosis markers which had shown to be associated with
histological injury variables. Tables 3, 4 and 5 show the diagnostic
accuracy of each marker by means of the sensitivity, specificity,
positive and negative predictive values.
When considering a less invasive test as good as a liver biopsy to
evaluate liver damage, the AUROC of the marker must be equal
to or greater than 0.800 [6]. Therefore, in this study, only those
markers which AUROC was greater than this value were taken
into account. Thus, sFas quantification demonstrated a limited
utility as a less invasive marker of significant fibrosis in pediatric
patients (AUROC: 0.719), but it could be considered a possible
marker of advanced fibrosis both in children and adults (children
AUROC: 0.812, NPV 100%, adults AUROC: 0.800, NPV 100%)
(Table 3). On the other hand, M30 showed an AUROC of 0.833
and a high NPV (100%) indicating that it might be a good marker
of steatosis severity in pediatric patients (Table 4). Finally, despite
the observed association between caspase activity and significant
fibrosis stage in pediatric patients as well as moderate/severe
hepatitis in adults, this marker would not be useful as a less
invasive indicator of liver damage. Although, both specificity and
PPV were high, AUROC values were very low (Table 5).
The cut off value for sFas to differentiate advanced fibrosis in
pediatric patients was 7416.56 pg/ml (100% Se, 55% Sp), whereas
in adults it was 13806.67 pg/ml (100% Se, 70.60% Sp) (Table 3).
Serum M30 cut off value for diagnosis of severe steatosis in
pediatric patients was 114.53 U/L (100% Se, 57.14% Sp)
(Table 4).
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Discussion
Apoptosis has been implicated in the pathogenesis of a number
of hepatic disorders, including viral hepatitis, autoimmune
diseases, non-alcoholic steatohepatitis, alcohol-induced injury,
cholestasis and hepatocellular cancer [23,24,25,26,27]. There is
increasing evidence suggesting that liver cell damage in CHC is
mediated by apoptosis induction, which has been proposed in view
of pathomorphologic features of infected hepatocytes
[17,24,28,29]. Several viral proteins display either apoptotic or
antiapoptotic features according to the model under study [18,30];
in turn, both in vitro studies or in vivo models with whole virus
demonstrated its ability to induce apoptosis. Our previous study
Table 2. Clinical, virological and histological features of adult CHC patients.
Clinical and serological characteristics Histological characteristics*
Adult
Patients Sex
Ages
(ys)
Risk factor for
HCV infection Genotype Transaminases Knodell
Fibrosis
stages #
Lymphoid
Follicle
Bile duct
damage Steatosis
AST (U/L) ALT (U/L)
1 M 38 Unknown 1b 82 89 6(5+1) F1 yes yes absent
2 F 52 T 1b 45 52 8(6+2) F1 yes yes minimal
3 M 42 Unknown 1a 44 56 9(8+1) F1 yes yes absent
4 F 62 T 1a 42 32 11(7+4) F3 no yes moderate
5 M 48 DA 1b 40 63 10(7+3) F2 no yes severe
6 M 40 DA 1a 34 45 10(6+4) F3 yes yes moderate
7 M 47 Unknown 1a 29 54 8(6+2) F1 yes yes minimal
8 M 40 DA 2a 63 79 4(4+0) F0 yes no absent
9 M 41 DA 3a 79 86 7(4+3) F2 no yes absent
10 F 61 Unknown 1a 31 28 17(12+5) F3 yes yes absent
11 F 72 Unknown 1a/c 52 71 9(6+3) F2 yes yes minimal
12 F 74 T 1* 106 85 15(12+3) F2 yes yes absent
13 M 62 Unknown 1b 22 32 10(7+3) F2 no yes absent
14 F 55 Unknown 3b 49 60 8(6+2) F1 yes yes severe
15 F 67 Unknown 2a 28 26 6(6+0) F0 yes yes minimal
16 F 41 Unknown 1a 192 105 6(2+4) F3 yes yes absent
17 M 51 OE 1b 65 74 5(4+0) F0 yes yes absent
18 M 51 DA 1a 73 109 10(7+3) F2 yes yes minimal
19 F 67 T 1b 106 103 13(9+4) F3 yes yes absent
20 M 73 Unknown 1b 31 42 8(6+2) F1 yes yes absent
21 M 41 DA 1a 32 50 10(7+3) F2 yes yes severe
22 M 47 DA 3 38 59 3(2+1) F1 yes yes minimal
F: female, M: male.
*Subtype not determined Risk factor for HCV infection: T: transfusion, DA: drug abuse, OE: occupational exposure.
ALT: alanine aminotransferase; AST: aspartate aminotransferase. Normal ALT and AST levels were #40 and #42 IU/L, respectively when test was done at 37uC.
#Fibrosis stages according METAVIR.
doi:10.1371/journal.pone.0053519.t002
Figure 1. Apoptosis markers in serum samples from CHC patients vs healthy subjects. *p,0.05; ** p,0.001; ***p,0.0001;?# trend of
association p,0.07.
doi:10.1371/journal.pone.0053519.g001
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demonstrated that apoptosis of hepatocytes is a prominent feature
observed in liver biopsies of patients with CHC and that it is
related to the pathogenesis of the disease [20]. Here, we evaluated
whether the apoptosis markers were a remarkable feature in serum
samples of pediatric and adult CHC patients and analyzed their
relation to liver damage. According to available data and their
importance in the pathogenesis, three components of the apoptosis
process were selected for evaluation: 1) sFas, since it has been
proposed that apoptosis triggered by Fas/FasL is a major cause of
hepatocyte damage together with the observed high Fas/FasL
expression levels which correlate with liver injury during CHC
[31,32,33,34,35]; 2) caspase activity, since it has been reported that
caspases are activated in HCV infected patient hepatocytes and
are responsible for most of the morphological changes of the
apoptotic cells [36]; and 3) M30, since CK18 is the major
intermediate filament of hepatocytes which is, in turn, a caspase
substrate whose cleavage contribute to cellular collapse during
apoptosis.
According to previously published data, this study showed that
serum sFas levels were high in patients with CHC
[31,37,38,39,40,41,42]; however, the clinical relevance of circu-
lating sFas is not completely understood. As described above, Fas/
FasL interaction is the primary initiator of the extrinsic apoptosis
pathway in the liver, hence the elimination of apoptotic bodies in
pathological conditions may induce an inflammatory reaction with
the consequent activation of stellate cells, which in turn favors the
development of liver fibrosis [43]. Several authors postulated that
sFas is associated with liver damage severity because significantly
increased sFas levels were observed in patients with terminal
disease stages such as cirrhosis and HCC [31,44]. In turn, Toyoda
et al reported that sFas levels in CHC patients correlated with
hepatitis severity [45]. Kakiuchi et al corroborated this result, but
on the other hand, reported that this marker is not associated with
fibrosis severity [40]. In contrast, the results herein indicated that
sFas was not related to hepatitis severity, but instead was
associated with fibrosis severity. It is important to note that
despite the higher sFas levels detected in CHC children compared
to healthy subjects, only a trend of association was observed. A
possible explanation for this observation would be that sFas levels
in pediatric patients with mild fibrosis stages were similar to those
of pediatric healthy subjects; furthermore in our studied series the
group of children with severe fibrosis was small since a severe stage
Figure 2. Serum markers related to liver damage in CHC patients. a) fibrosis, b) hepatitis and c) steatosis severity. Fibrosis stages according
METAVIR. Significant fibrosis (F$2) and advanced fibrosis (F$3). * p,0.05;?# trend of association p,0.08.
doi:10.1371/journal.pone.0053519.g002
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of fibrosis is not commonly present in CHC patients during
infancy and childhood.
With respect to activation of caspases, the current results
corroborate that apoptosis is an important event in CHC, as we
have previously observed when investigating caspase activity and
M30 expression in liver samples from CHC patients [20]. The
assessment of caspases activation and M30 showed high values in
the two types of samples tested, but in none of the two age groups
these markers detected on liver biopsies correlated with their
corresponding marker in serum. Since liver and serum are distinct
compartments, one possible explanation for the lack of correlation
may be that apoptotic cells are rapidly eliminated and therefore,
would not be detected in biopsy. Meanwhile, although the exact
mechanism of secretion of M30 in the blood has not been
determined yet, it is postulated that serum M30 is released as a
result of necrosis secondary to apoptosis. In favor of the latter, we
observed correlations between M30 and terminal apoptotic cells
(TUNEL+ cells) in both pediatric and adult patients (pediatric
patients r = 0.533 p = 0.02; adult patients r = 0.535 p = 0.02) (for
technical information see Methods S1).
According to that previously described for adult cohorts [28],
M30 levels and caspase activity were significantly increased in
serum samples from pediatric and adult patients with respect to
control subjects. However, their relation to liver damage is still
controversial. Bantel et al found that serum M30 quantification is
a highly sensitive method to early detect fibrosis severity [28].
They observed that M30 levels were associated with more severe
stages of fibrosis only in patients with normal transaminase values,
but no association between M30 and either hepatitis or fibrosis
severity in general adult CHC patients was found. On the other
hand, Seidel et al found that both M30 and caspase activity were
elevated in adult patients with severe steatosis [46]. Finally,
Papatheodoridis et al found that M30 is associated with global
liver damage severity, because its levels correlated with hepatitis
severity, fibrosis and steatosis [47]. In contrast, Joka et al describe
that M65, another epitope which is present in both caspase-
cleaved and uncleaved CK-18, is more sensitive and specific than
M30 for the detection of lower fibrosis stages and steatosis severity
in many forms of chronic liver disease, including CHC; although
M65 and M30 were not individually analyzed in the context of
each disease etiology [48]. In our report each marker showed a
different association profile related to liver damage in each of the
studied cohorts. Higher levels of caspase activity were observed in
adult cases with more severe hepatitis as well as in children with
significant fibrosis. While M30 showed a trend of association with
advanced fibrosis, it did not correlate with steatosis degree in adult
patients. Concerning children, this marker was significantly
increased in cases with severe steatosis. This last finding is
particularly important since M30 is being widely studied as a
marker of the steatosis severity both in pediatric and adult patients
with Non Alcoholic Steatohepatitis [49,50,51,52,53,54].T
a
b
le
3
.
D
ia
g
n
o
st
ic
ac
cu
ra
cy
o
f
sF
as
fo
r
si
g
n
if
ic
an
t
an
d
ad
va
n
ce
fi
b
ro
si
s
in
C
H
C
p
at
ie
n
ts
.
S
IG
N
IF
IC
A
N
T
F
IB
R
O
S
IS
(F
$
2
)
A
U
R
O
C
9
5
%
C
I
C
u
t
o
ff
*
S
e
%
S
p
%
P
P
V
N
P
V
P
E
D
IA
T
R
IC
P
A
T
IE
N
T
S
0
.7
1
9
0
.5
0
0
–
0
.8
8
1
6
8
1
5
.1
4
8
6
.6
7
5
5
.5
6
7
6
.5
7
1
.4
A
D
V
A
N
C
E
D
F
IB
R
O
S
IS
(F
$
3
)
A
U
R
O
C
9
5
%
C
I
C
u
t
o
ff
*
S
e
%
S
p
%
P
P
V
N
P
V
P
E
D
IA
T
R
IC
P
A
T
IE
N
T
S
0
.8
1
2
0
.6
0
2
–
0
.9
4
1
7
4
1
6
.5
6
1
0
0
5
5
3
0
.8
1
0
0
A
D
U
L
T
P
A
T
IE
N
T
S
0
.8
0
0
0
.5
7
7
–
0
.9
3
8
1
3
8
0
6
.6
7
1
0
0
7
0
.6
0
5
0
1
0
0
*p
g
/m
l.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
5
3
5
1
9
.t
0
0
3
Table 4. Diagnostic accuracy of M30 for steatosis severity in
pediatric CHC patients.
SEVERE STEATOSIS
AUROC 95% CI Cut off * Se% Sp% PPV NPV
PEDIATRIC
PATIENTS
0.833 0.634–0.951 114.53 100 57.14 30.8 100
*U/L.
doi:10.1371/journal.pone.0053519.t004
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A major clinical challenge is finding the best means for
evaluating liver impairment in the increasing number of CHC
infected patients [2,9,55]. Prognosis and treatment of CHC are
partly dependent on the assessment of histological activity, namely
cell necrosis and inflammation, and on the degree of liver fibrosis.
These parameters have so far been provided by liver biopsy,
because conventional laboratory tests are unable to precisely
evaluate liver lesions. Biopsy, due to its limitations and risks, is no
longer considered mandatory as the 1st-line indicator of liver
injury in CHC patients [56,57,58,59]. In addition to the risks
related to an invasive procedure, liver biopsy has been associated
with sampling errors mostly due to suboptimal biopsy size
[60,61,62]. To avoid these pitfalls, several markers have been
proposed as noninvasive alternatives for predicting liver damage;
but few, particularly those which combine clinical and biochemical
parameters, have been applied to pediatric patients [63,64]. In this
study, the observed relationships between sFas, M30 and caspase
activity and liver damage prompted us to assess the diagnostic
value of apoptosis markers as potential indicators of liver damage.
Herein, based on AUROC values it was demonstrated that sFas
could be a marker of advanced fibrosis both in children and adults
and, in turn, M30 could be a good predictor of steatosis severity in
children. However, despite the observed association between
caspase activity and significant fibrosis in children as well as with
hepatitis severity in adult patients, this marker would not be useful
as a less invasive indicator of liver damage. Unfortunately,
although there are many studies that evaluate these serum
apoptosis markers in CHC patients related to liver damage, they
do not assess their diagnostic value. This makes it impossible to
compare the determined diagnostic accuracy of these markers for
the diagnosis of liver injury severity with other reports.
There are several articles that analyze AST-to-platelet ratio
(APRI) and AST-to-ALT ratio (AAR) as surrogate indirect serum
markers of liver fibrosis. As we previously describe when assessed
in our cohorts [15], these approaches did not improve the
diagnostic accuracy performance of sFas in pediatric series, since
neither APRI nor AAR reached the 0.800 AUROC value
proposed to be enough for staging fibrosis. In adults APRI
showed a low performance which does not reach the 0.800
AUROC value, while AAR diagnostic value is comparable with
the sFas one to predict advanced fibrosis (Table S1).
It should not be ignored that the present study has certain
limitations. First, this was in fact a retrospective study, with a quite
limited number of cases, so this makes it difficult to validate the
utility of serum markers. Second, due to medical management
protocols from our institutions, pediatric patients without liver
fibrosis (F0) and adults with cirrhosis or hepatic decompensation
were not available for this study. Third, since we did not take into
account biopsy length and fragmentation, the potential for
sampling error and understaging of fibrosis remains possible.
Anyway, the molecules here proposed turned out to be easily
measurable markers, which can be interpreted in a simple manner.
The study of a larger number of cases, perhaps in a multicenter
study, will confirm the results obtained in this work and discuss the
possibility of adding apoptosis markers to panels that included
matrix deposition, clinical and biochemical parameters. Taking
into account our previous results on fibrogenesis process direct
markers (15) (Table S1), we propose the addition of apoptosis
markers, particularly sFas combined with TIMP-1 in pediatric
patients and sFas with TGF-ß1, HA, PIIINP in adult patients to
more accurately assess liver fibrosis severity.
In conclusion, serum sFas could be considered a possible marker
of advanced fibrosis both in pediatric and adult patient with CHC
as well as M30 could be a good predictor of steatosis severity in
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children. Perhaps if these parameters are validated in the near
future, they could be easily performed and interpreted and,
therefore, could be potentially translatable to the bedside.
Supporting Information
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(DOC)
Table S1 AUROC for advance fibrosis.
(DOC)
Acknowledgments
The authors thank Dr Rey Rodolfo (CEDIE-CONICET, HNRG) for his
help with the chemiluminescence assay and Livellara B (Liver Unit, HIBA)
for preserving adult serum samples.
Author Contributions
Performed pathological reviews: EDM EM. Assisted in data interpretation
and analysis: PC MG CL OG AG MCG. Conceived and designed the
experiments: PV MVP. Performed the experiments: PV. Analyzed the
data: PV MVP PC. Contributed reagents/materials/analysis tools: EDM
EM PC MG CL OG AG MCG. Wrote the paper: PV PC MVP.
References
1. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29 74–81.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management,
and treatment of hepatitis C: an update. Hepatology 49: 1335–1374.
3. Mohan N, Gonzalez-Peralta RP, Fujisawa T, Chang MH, Heller S, et al. (2010)
Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr 50:
123–131.
4. Bravo A, Sheth S, Chopra S (2001) Liver biopsy. N Engl J Med 344: 495–500.
5. Thampanitchawong P, Piratvisuth T (1999) Liver biopsy:complications and risk
factors. World J Gastroenterol 5: 301–304.
6. Afdhal N, Nunes D (2004) Evaluation of liver fibrosis: a concise review.
Am J Gastroenterol 99: 1160–1174.
7. Martı´nez SM, Crespo G, Navasa M, X F (2011) Noninvasive assessment of liver
fibrosis. Hepatology 53: 325–335.
8. Manning D, Afdhal N (2008) Diagnosis and quantitation of fibrosis.
Gastroenterology 134: 1670–1681.
9. Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, et al. (2011) A brief review on
molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J
8: 53.
10. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, et al. (2011) A comparison of
four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis
index (FCI). BMC Gastroenterol 11: 44.
11. Macı´as J, Mira J, Gilabert I, Neukam K, Rolda´n C, et al. (2011) Combined use
of aspartate aminotransferase, platelet count and matrix metalloproteinase 2
measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected
patients. HIV Med 12: 12–21.
12. Moreno S, Garcı´a-Samaniego J, Moreno A, Ortega E, Pineda J, et al. (2009)
Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/
HBV co-infection. Viral Hepat 16: 249–258.
13. Forns X, Ampurdane`s S, Llovet J, Aponte J, Quinto´ L, et al. (2002)
Identification of chronic hepatitis C patients without hepatic fibrosis by a
simple predictive model. Hepatology 36: 986–992.
14. Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, et al. (2011) The impact of
liver disease aetiology and the stages of hepatic fibrosis on the performance of
non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment
Pharmacol Ther 34: 1202–1216.
15. Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, et al. (2011)
The role of serum biomarkers in predicting fibrosis progression in pediatric and
adult hepatitis C virus chronic infection. PLoS One 6: e23218.
16. Wyllie A, Kerr J, Currie A (1980) Cell death: the significance of apoptosis. Int
Rev Cytol 68: 251–306.
17. Bantel H, Schulze-Osthoff K (2003) Apoptosis in hepatitis C virus infection. Cell
Death Differ 10: S48–58.
18. Fischer R, Baumert T, Blum H (2007) Hepatitis C virus infection and apoptosis.
World J Gastroenterol 13: 4865–4872.
19. Rust C, Gores G (2000) Apoptosis and liver disease. Am J Med 108: 567–574.
20. Valva P, De Matteo E, Galoppo MC, Gismondi MI, Preciado MV (2010)
Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus
infection: M30 mirrors the severity of steatosis. J Med Virol 82: 949–957.
21. Theise N, Bordenheimer H, Ferrel L ( 2007) Acute and chronic viral hepatitis.
In: Burt AD, Portmann BC, Ferrel LD, editors. MacSweens Pathology of the
liver. London: Churchill-Livingstone. 5u edition cap 8: 418–419.
22. Consenso Argentino de Hepatitis C (2007) Documento final Consenso
Argentino Hepatitis C, Asociacio´n Argentina para el Estudio de las
Enfermedades del Hı´gado.
23. Ghavami S, Hashemi M, Kadkhoda K, Alavian S, Bay G, et al. (2005) Apoptosis
in liver diseases–detection and therapeutic applications. Med Sci Monit 11: 337–
345.
24. Que F, Gores G (1996) Cell death by apoptosis: basic concepts and disease
relevance for the gastroenterologist. Gastroenterology 110: 1238–1243.
25. Patel T, Gores G (1995) Apoptosis and hepatobiliary disease. Hepatology 21:
1725–1741.
26. Thompson C (1995) Apoptosis in the pathogenesis and treatment of disease.
Science 267: 1456–1462.
27. Zekri AR, Bahnassy AA, Hafez MM, Hassan ZK, Kamel M, et al. (2011)
Characterization of chronic HCV infection-induced apoptosis. Comp Hepatol
10: 4.
28. Bantel H, Lu¨gering A, Heidemann J, Volkmann X, Poremba C, et al. (2004)
Detection of apoptotic caspase activation in sera from patients with chronic
HCV infection is associated with fibrotic liver injury. Hepatology 40: 1078–
1087.
29. Kerr J, Cooksley W, Searle J, Halliday J, Halliday W, et al. (1979) The nature of
piecemeal necrosis in chronic active hepatitis. Lancet 2: 827–828.
30. Mengshol J, Golden Mason L, Rosen H (2007) Mechanisms of Disease: HCV-
induced liver injury. Nat Clin Pract Gastroenterol Hepatol 4: 622–634.
31. El Bassiouny A, El-Bassiouni N, Nosseir M, Zoheiry M, El-Ahwany E, et al.
(2008) Circulating and hepatic Fas expression in HCV-induced chronic liver
disease and hepatocellular carcinoma. Medscape J Med 10: 130.
32. Bortolami M, Kotsafti A, Cardin R, Farinati F (2008) Fas/FasL system, IL-1beta
expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat
15: 515–522.
33. El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, et al. (2006)
Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth
factor receptor in hepatitis C virus infection, cirrhotic liver disease and
hepatocellular carcinoma. APMIS 114: 420–427.
34. Kanto T, Hayashi N (2006) Immunopathogenesis of hepatitis C virus infection:
multifaceted strategies subverting innate and adaptive immunity. Intern Med 45:
183–191.
35. Kiyici M, Gurel S, Budak F, Dolar E, Gulten M, et al. (2003) Fas antigen (CD95)
expression and apoptosis in hepatocytes of patients with chronic viral hepatitis.
Eur J Gastroenterol Hepatol 15: 1079–1084.
36. Bantel H, Lugering A, Poremba C, Lugering N, Held J, et al. (2001) Caspase
activation correlates with the degree of inflammatory liver injury in chronic
hepatitis C virus infection. Hepatology 34: 758–767.
37. Panasiuk A, Parfieniuk A, Zak J, Flisiak R (2010) Association among Fas
expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic
inflammation and fibrosis in chronic hepatitis C. Liver Int 30: 472–478.
38. Zaki Mel S, Auf FA, Ghawalby NA, Saddal NM (2008) Clinical significance of
serum soluble Fas, Fas ligand and fas in intrahepatic lymphocytes in chronic
hepatitis C. Immunol Invest 37: 163–170.
39. Raghuraman S, Abraham P, Daniel HD, Ramakrishna BS, Sridharan G (2005)
Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha
in patients with chronic HCV infection. J Clin Virol 34: 63–70.
40. Kakiuchi Y, Yuki N, Iyoda K, Sugiyasu Y, Kaneko A, et al. (2004) Circulating
soluble Fas levels in patients with hepatitis C virus infection and interferon
therapy. J Gastroenterol 39: 1189–1195.
41. Lapinski TW, Kowalczuk O, Prokopowicz D, Chyczewski L (2004) Serum
concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral
hepatitis B and C patients. World J Gastroenterol 10: 3650–3653.
42. Ozaslan E, Kilicarslan A, Simsek H, Tatar G, Kirazli S (2003) Elevated serum
soluble Fas levels in the various stages of hepatitis C virus-induced liver disease.
J Int Med Res 31: 384–391.
43. Canbay A, Friedman S, Gores G (2004) Apoptosis: the nexus of liver injury and
fibrosis. Hepatology 39: 273–278.
44. Zekri AR, Alam El-Din HM, Bahnassy AA, Zayed NA, Mohamed WS, et al.
(2010) Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II,
interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular
carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp
Hepatol 9: 1.
45. Toyoda M, Kakizaki S, Horiguchi N, Sato K, Takayama H, et al. (2000) Role of
serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-
alpha therapy in chronic hepatitis C. Liver 20: 305–311.
46. Seidel N, Volkmann X, Langer F, Flemming P, Manns M, et al. (2005) The
extent of liver steatosis in chronic hepatitis C virus infection is mirrored by
caspase activity in serum. Hepatology 42: 113–120.
47. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, et al.
(2010) Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic
Fatty liver disease. J Clin Gastroenterol 44: e87–95.
48. Joka D, Wahl K, Moeller S, Schlue J, Vaske B, et al. (2012) Prospective biopsy-
controlled evaluation of cell death biomarkers for prediction of liver fibrosis and
nonalcoholic steatohepatitis. Hepatology 55: 455–464.
Serum Apoptosis Markers in CHC
PLOS ONE | www.plosone.org 9 January 2013 | Volume 8 | Issue 1 | e53519
49. Lebensztejn DM, Wierzbicka A, Socha P, Pronicki M, Skiba E, et al. (2011)
Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with
non-alcoholic fatty liver disease. Acta Biochim Pol 58: 563–566.
50. Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, et al. (2011) An
apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54: 1224–
1229.
51. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, et al. (2009)
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic
steatohepatitis: a multicenter validation study. Hepatology 50: 1072–1078.
52. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, et al. (2007) Soluble forms of
extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic
steatohepatitis. World J Gastroenterol 13: 837–844.
53. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, et al. (2010)
Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and
fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 51: 500–506.
54. Wieckowska A, Zein N, Yerian L, Lopez A, McCullough A, et al. (2006) In vivo
assessment of liver cell apoptosis as a novel biomarker of disease severity in
nonalcoholic fatty liver disease. Hepatology 44: 27–33.
55. Kershenobich D, Razavi HA, Sanchez-Avila JF, Bessone F, Coelho HS, et al.
(2011) Trends and projections of hepatitis C virus epidemiology in Latin
America. Liver Int 31 Suppl 2: 18–29.
56. Castera L, Pinzani M (2010) Biopsy and non-invasive methods for the diagnosis
of liver fibrosis: does it take two to tango? Gut 59: 861–866 2010.
57. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, et al. (2002)
Role of liver biopsy in management of chronic hepatitis C: a systematic review.
Hepatology 36: S161–172.
58. Poynard T, Ratziu V, Benhamou Y, Thabut D, Moussalli J (2005) Biomarkers as
a first-line estimate of injury in chronic liver diseases: time for a moratorium on
liver biopsy?. Gastroenterology 128: 1146–1148
59. Sebastiani G, Alberti A (2006) Non invasive fibrosis biomarkers reduce but not
substitute the need for liver biopsy. World J Gastroenterol 12: 3682–3694.
60. Poynard T, Halfon P, Castera L, Charlotte F, Le Bail B, et al. (2007) Variability
of the area under the receiver operating characteristic curves in the diagnostic
evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
Aliment Pharmacol Ther 25: 733–739.
61. Colloredo G, Guido M, Sonzogni A, G L (2003) Impact of liver biopsy size on
histological evaluation of chronic viral hepatitis: the smaller the sample, the
milder the disease. J Hepatol 39: 239–244.
62. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling
error and intraobserver variation in liver biopsy in patients with chronic HCV
infection. Am J Gastroenterol 97: 2614–2618.
63. Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, et al. (2010)
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus
infection. Gastroenterol Clin Biol 34: 16–22.
64. El-Shabrawi MH, Mohsen NA, Sherif MM, El-Karaksy HM, Abou-Yosef H, et
al. (2010) Noninvasive assessment of hepatic fibrosis and necroinflammatory
activity in Egyptian children with chronic hepatitis C virus infection using
FibroTest and ActiTest. Eur J Gastroenterol Hepatol 22: 946–951.
Serum Apoptosis Markers in CHC
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e53519
